Xeris Biopharma (NASDAQ:XERS) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen downgraded shares of Xeris Biopharma (NASDAQ:XERS) from a strong-buy rating to a buy rating in a research note released on Saturday morning.

Separately, Weiss Ratings raised Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Xeris Biopharma Stock Up 7.7%

Shares of XERS stock opened at $7.93 on Friday. Xeris Biopharma has a 12-month low of $5.25 and a 12-month high of $10.08. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The firm has a fifty day moving average of $7.68 and a 200-day moving average of $6.80. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -72.09 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). The company had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 158.10%. As a group, equities research analysts predict that Xeris Biopharma will post 0.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director John Johnson sold 15,000 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $91,350.00. Following the sale, the director owned 683,083 shares of the company’s stock, valued at $4,159,975.47. The trade was a 2.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 15,000 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $8.02, for a total transaction of $120,300.00. Following the transaction, the insider owned 1,676,126 shares of the company’s stock, valued at $13,442,530.52. The trade was a 0.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 266,499 shares of company stock valued at $1,996,417 over the last ninety days. Insiders own 4.35% of the company’s stock.

Institutional Trading of Xeris Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of XERS. Royal Bank of Canada boosted its position in Xeris Biopharma by 1,411.2% during the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after purchasing an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after purchasing an additional 3,594 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after buying an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after buying an additional 1,199,435 shares during the last quarter. Finally, Caxton Associates LLP bought a new position in shares of Xeris Biopharma in the first quarter valued at $170,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.